Glenn D. Braunstein, MD, Honored With Mastership From American College of Physicians

Los Angeles - June 17, 2008 - Glenn D. Braunstein, MD, chair of the Department of Medicine at Cedars-Sinai and a nationally known endocrinologist, has been honored with a Mastership by the American College of Physicians (ACP).

ACP Masters are a small group of highly distinguished physicians who have achieved recognition in medicine by exhibiting excellence in practice or medical research, holding positions of high honor, or making significant contributions to medical science or the art of medicine.

“The ACP is the preeminent organization representing internal medicine in the United States. The ACP goals are to promote access to the highest quality of evidence-based medical care to all patients. The College emphasizes professionalism, humanism, and lifelong learning among practitioners. I am deeply honored and humbled to receive this wonderful recognition from my peers in the College," said Braunstein, who has been a Cedars-Sinai physician for more than 35 years.

Braunstein, holder of the James R. Klinenberg, MD, Chair in Medicine, is also associate director of the Center for Androgen Related Disorders and medical director of the Thyroid Cancer Center of Excellence at Cedars-Sinai. He is board certified in internal medicine with a subspecialty of endocrinology, diabetes and metabolism. His research has been primarily in the fields of reproductive endocrinology and thyroid cancer. Braunstein has made fundamental contributions in endocrinology, particularly relating to placental hormones, thyroid cancer, and testosterone therapy for women. He has written for more than 300 publications and has served on the editorial boards of 12 journals, including serving as editor for the Journal of Clinical Endocrinology & Metabolism and as associate editor for Integrative Medicine. He has also chaired the Subspecialty Board on Endocrinology, Diabetes, and Metabolism for the American Board of Internal Medicine and served on the Endocrinologic and Metabolic Drugs Advisory Committee for the U.S. Food and Drug Administration.